Is Mednax Holding Company (NYSE:MD) a Buy? The Stock Reported Less Sellers

February 15, 2018 - By Michael Collier

 Is Mednax Holding Company (NYSE:MD) a Buy? The Stock Reported Less Sellers

The stock of Mednax Holding Company (NYSE:MD) registered a decrease of 10.08% in short interest. MD’s total short interest was 5.63 million shares in February as published by FINRA. Its down 10.08% from 6.26M shares, reported previously. With 2.45 million shares average volume, it will take short sellers 2 days to cover their MD’s short positions. The short interest to Mednax Holding Company’s float is 6.2%.

The stock increased 2.94% or $1.61 during the last trading session, reaching $56.37. About 582,220 shares traded. MEDNAX, Inc. (NYSE:MD) has declined 18.20% since February 15, 2017 and is downtrending. It has underperformed by 34.90% the S&P500.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company has market cap of $5.23 billion. The firm offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. It has a 19.98 P/E ratio. It also provides maternal-fetal care, including inpatient and office clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors.

MEDNAX, Inc. (NYSE:MD) Ratings Coverage

Among 18 analysts covering MEDNAX (NYSE:MD), 5 have Buy rating, 1 Sell and 12 Hold. Therefore 28% are positive. MEDNAX had 50 analyst reports since July 31, 2015 according to SRatingsIntel. On Friday, November 3 the stock rating was maintained by Robert W. Baird with “Neutral”. Jefferies maintained MEDNAX, Inc. (NYSE:MD) on Thursday, August 31 with “Hold” rating. Robert W. Baird maintained the stock with “Hold” rating in Thursday, February 8 report. As per Thursday, October 5, the company rating was maintained by Robert W. Baird. The firm has “Buy” rating given on Tuesday, August 25 by Stifel Nicolaus. The rating was initiated by JP Morgan on Wednesday, September 16 with “Overweight”. The rating was downgraded by Jefferies to “Hold” on Tuesday, December 13. Raymond James downgraded the stock to “Mkt Perform” rating in Thursday, October 27 report. The firm earned “Hold” rating on Thursday, August 31 by Stifel Nicolaus. The stock of MEDNAX, Inc. (NYSE:MD) earned “Hold” rating by Robert W. Baird on Friday, September 1.

More news for MEDNAX, Inc. (NYSE:MD) were recently published by: Streetinsider.com, which released: “MEDNAX, INC.” on February 08, 2018. Gurufocus.com‘s article titled: “BTIM Corp. Buys Eversource Energy, Mednax Inc, Honeywell International Inc …” and published on January 29, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: